Get the Stockscreener App
2.05
33.76%
-1.09
After Hours:
2.16
0.11
+5.37%
Silexion Therapeutics Corp stock is traded at $2.05, with a volume of 14.03M.
It is down -33.76% in the last 24 hours and down -8.37% over the past month.
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
See More
Previous Close:
$3.14
Open:
$2.23
24h Volume:
14.03M
Relative Volume:
1.42
Market Cap:
$7.79M
Revenue:
-
Net Income/Loss:
$-16.42M
P/E Ratio:
-0.0879
EPS:
-23.3189
Net Cash Flow:
$-6.75M
1W Performance:
+216.06%
1M Performance:
-8.37%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.87
$2.30
1-Week Range:
$0.575
$3.45
52-Week Range:
$0.575
$23.13
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
2.05 | 7.79M | 0 | -16.42M | -6.75M | -23.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
3 Penny Stocks to Watch Now, 1/30/25 - TipRanks
Silexion Therapeutics announces exercise of warrants for $3.3M gross proceeds - MSN
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds - GlobeNewswire
Cancer Drug Developer Silexion Raises Millions in Clever Financial MoveHere's the Deal - StockTitan
Stock market news: Signing Day Sports +124.23%, Silexion Therapeutics +80.74% among top gainers during mid day trading - Business Upturn
Stock market today: Signing Day Sports +200.52%, Silexion Therapeutics +69.63% among top gainers in early trading - Business Upturn
Revolutionary Cancer Treatment Achieves 50% Tumor Reduction, Outperforms Industry Standards - StockTitan
Silexion (SLXN) Stock Rallies In Pre-Hour Market Amid Promising Study Results - Stocks Telegraph
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings - Benzinga
Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday? - AOL
Gold Gains 1%; Boeing Shares Rise Following Q4 Results - Benzinga
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results - Benzinga
Silexion Therapeutics Surge in Recent Trading Amid 'Promising' Preclinical Data From Tumor Drug Candidate - Marketscreener.com
Silexion reports breakthrough in KRAS cancer therapy - MSN
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings - Benzinga
Silexion Therapeutics reports preclinical data for SIL-204 - TipRanks
Silexion Therapeutics Reports Strong Tumor Growth Reduction - GlobeNewswire
Revolutionary Cancer Treatment Cuts Tumors in Half: Silexion's New Drug Targets Multiple KRAS Mutations - StockTitan
TSMC Leads Pre-Market Gains After Record Q4 Earnings; Other Stocks See Volatility - HPBL
SLXN stock touches 52-week low at $0.82 amid sharp annual decline - Investing.com Australia
Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures - MSN
Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies - Benzinga
Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data End - Asianet Newsable
Silexion Therapeutics drops 18%, prices $5M share offering - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Silexion Therapeutics Raises $5M in Public Offering to Advance RNA Cancer Therapies - StockTitan
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering - GlobeNewswire
Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics - MarketWatch
Silexion Therapeutics Shares Jump After Pancreatic-Cancer Treatment Data - MarketWatch
Silexion Shares Rise Late Following Pretrial Data From Pancreatic Cancer Treatment Showing Efficacy - Marketscreener.com
Silexion Therapeutics announces new preclinical results for SIL-204 - TipRanks
Silexion Therapeutics Announces Additional Promising - GlobeNewswire
Silexion's New Cancer Drug Shows Powerful Synergy with Chemo in Pancreatic Cancer Study - StockTitan
Silexion Therapeutics to Present SIL-204 Data in - GlobeNewswire
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium - Yahoo Finance
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
SLXN stock touches 52-week low at $1.82 amid market challenges - Investing.com
BioLineRx Announces $10 Million Registered Direct Offering - Quantisnow
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Silexion Therapeutics, Evonik collaborate on siRNA formulation development - Yahoo Finance
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises - Business Wire
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development - GlobeNewswire
Premarket movers: GE Vernova, Walgreens Boots Alliance - MarketWatch
Silexion Therapeutics Corp Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
SEC Form 424B3 filed by Silexion Therapeutics Corp - Quantisnow
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors - GlobeNewswire
Silexion Therapeutics Strengthens Board with Cancer Research Pioneer Prof. Amnon Peled - StockTitan
Stock market news: Silexion Therapeutics Corp -88.65%, Applied Therapeutics -75.55% among biggest losers during mid day trading - Business Upturn
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.46%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):